AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19394194 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment Model (CT)
Number of subjects: 147
Study 19394194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 147
Study 16928222 — intervention group
Group type: EXPERIMENTAL
Intervention: PBAT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., amoxicillin‐clavulanate 1000 mg b.i.d., and tetracycline 500 mg q.i.d.)
Number of subjects: 54
Study 16928222 — intervention group
Group type: COMPARATOR
Intervention: PBMT (pantoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d.)
Number of subjects: 54
Study 15173146 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g monthly)
Number of subjects: 466
Study 15173146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 11340690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal triamcinolone acetonide 220 micrograms/day for six months
Number of subjects: 92
Study 11340690 — intervention group
Group type: COMPARATOR
Intervention: Oral cetirizine 10 mg/day
Number of subjects: 92
Study 11340690 — intervention group
Group type: COMPARATOR
Intervention: Intranasal beclomethasone dipropionate 400 micrograms/day
Number of subjects: 92
Study 11340690 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 92
Study 9325511 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Epidural Infusor (PCEA) using pethidine
Number of subjects: 20
Study 9325511 — intervention group
Group type: COMPARATOR
Intervention: Standard electronic device for PCEA using pethidine
Number of subjects: 20
Study 8076759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment (8.4-336 megaunits)
Number of subjects: 90
Study 3065499 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertion of a long-term ventilation tube
Number of subjects: 50
Study 3065499 — intervention group
Group type: COMPARATOR
Intervention: Control (non-ventilated ear)
Number of subjects: 50
Study 31464189 — intervention group
Group type: EXPERIMENTAL
Intervention: iMHere mobile health system
Number of subjects: 38
Study 31464189 — intervention group
Group type: COMPARATOR
Intervention: Standard care without technology intervention
Number of subjects: 38
Study 28848330 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt supplemented with Lactobacillus paracasei N1115, 300 mL/d for 12 weeks
Number of subjects: 205
Study 28848330 — intervention group
Group type: COMPARATOR
Intervention: Normal diet without probiotic supplementation
Number of subjects: 205
Study 25187210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12
Study 25187210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12
Study 25187210 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg intranasal scopolamine gel (INSCOP)
Number of subjects: 12
Study 25187210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23261001 — intervention group
Group type: EXPERIMENTAL
Intervention: No significant CAD
Number of subjects: 127
Study 23261001 — intervention group
Group type: COMPARATOR
Intervention: CAD
Number of subjects: 127
Study 21711137 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA StoneBreaker™ (SB)
Number of subjects: 77
Study 21711137 — intervention group
Group type: COMPARATOR
Intervention: Swiss LithoClast® (LC)
Number of subjects: 77
Study 19359109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone treatment
Number of subjects: 0
Study 19359109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17130977 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemo radiotherapy
Number of subjects: 0
Study 17130977 — intervention group
Group type: COMPARATOR
Intervention: Macdonald study protocol
Number of subjects: 0
Study 12757115 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% long-chain triglycerides (phospholipid/triglyceride ratio: 0.04)
Number of subjects: 90
Study 12757115 — intervention group
Group type: COMPARATOR
Intervention: 20% long-chain triglycerides (phospholipid/triglyceride ratio: 0.06)
Number of subjects: 90
Study 11486797 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Imaging (TCDI)
Number of subjects: 29
Study 11486797 — intervention group
Group type: COMPARATOR
Intervention: Transcranial Doppler (TCD)
Number of subjects: 29
Study 11486797 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler Imaging (TCDI) after modifications
Number of subjects: 29
Study 9220523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported tobacco smoke exposure (mean number of cigarettes smoked per day in the infant's presence)
Number of subjects: 485
Study 9220523 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary cotinine/creatinine ratio
Number of subjects: 485
Study 8123410 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. clonidine 30 micrograms diluted in saline to a total volume of 5 ml, repeated every 5 min up to a maximum dose of 90 micrograms
Number of subjects: 40
Study 8123410 — intervention group
Group type: COMPARATOR
Intervention: saline 5 ml (placebo solution), repeated every 5 min up to a maximum of three boluses
Number of subjects: 40
Study 8123410 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo) after initial clonidine treatment
Number of subjects: 40
Study 3546120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer exercise for 60 minutes three times a week for 10 weeks
Number of subjects: 20
Study 3546120 — intervention group
Group type: COMPARATOR
Intervention: No physical training
Number of subjects: 20
Study 31039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of linezolid
Number of subjects: 48
Study 31039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of linezolid
Number of subjects: 48
Study 31039153 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term linezolid treatment
Number of subjects: 48
Study 29016675 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport group ingesting a drink high in protein (18 g) immediately and 3 h after each training session (TS-HP, n = 13)
Number of subjects: 48
Study 29016675 — intervention group
Group type: EXPERIMENTAL
Intervention: Team sport group ingesting an isocaloric drink with low protein content (3 g; TS-LP, n = 18)
Number of subjects: 48
Study 29016675 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing their normal activities (CON, n = 17)
Number of subjects: 48
Study 25569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring with a dedicated treatment guideline during the first 72 hours of life
Number of subjects: 166
Study 25569128 — intervention group
Group type: COMPARATOR
Intervention: Blinded NIRS monitoring with standard care
Number of subjects: 166
Study 25569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring
Number of subjects: 166
Study 25569128 — intervention group
Group type: COMPARATOR
Intervention: Blinded NIRS monitoring
Number of subjects: 166
Study 23686030 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 5 weeks
Number of subjects: 22
Study 23686030 — intervention group
Group type: EXPERIMENTAL
Intervention: rACC activity assessment
Number of subjects: 22
Study 21245735 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural (GAE)
Number of subjects: 226
Study 19799601 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 855 mg/kg
Number of subjects: 20
Study 19799601 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol 1710 mg/kg
Number of subjects: 20
Study 19799601 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy individuals) 1710 mg/kg
Number of subjects: 20
Study 16762943 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin (RMD)
Number of subjects: 17
Study 16762943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber fraction of RMD
Number of subjects: 17
Study 16762943 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 17
Study 16762943 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin
Number of subjects: 17
Study 15334859 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0
Study 15334859 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0
Study 15334859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 15334859 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 0
Study 11502796 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human IGF-I (40 microg/kg)
Number of subjects: 9
Study 11502796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (HEX)
Number of subjects: 9
Study 9258804 — intervention group
Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 9
Study 8506190 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin
Number of subjects: 20
Study 8506190 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin
Number of subjects: 20
Study 2891534 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam administered at 0900 h (day-time)
Number of subjects: 12
Study 2891534 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg temazepam administered at 2200 h (night-time)
Number of subjects: 12
Study 29668919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 0
Study 29668919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 27527391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX) - initial dose of 1 µg/kg for 10 min followed by continuous infusion at 0.3 µg/kg/h until the end of surgery.
Number of subjects: 80
Study 27527391 — intervention group
Group type: COMPARATOR
Intervention: Control group - saline treatment.
Number of subjects: 80
Study 24680359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (ART) with 60 Gy
Number of subjects: 388
Study 24680359 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see (WS)
Number of subjects: 388
Study 24680359 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (ART)
Number of subjects: 388
Study 22686491 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BoNT‐A) injections and abduction bracing
Number of subjects: 46
Study 22686491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison group)
Number of subjects: 46
Study 20980426 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised walking sessions (3 times per week) and counseling
Number of subjects: 59
Study 20980426 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle recommendations
Number of subjects: 59
Study 18828921 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAG mobilisation
Number of subjects: 49
Study 18828921 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilisation
Number of subjects: 49
Study 16355089 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD Express Compression System
Number of subjects: 12
Study 16355089 — intervention group
Group type: COMPARATOR
Intervention: VenaFlow (rapid inflation device)
Number of subjects: 12
Study 12002407 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement 1U/day
Number of subjects: 24
Study 12002407 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement 2U/day
Number of subjects: 24
Study 12002407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10202820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg twice daily and Saquinavir 400 mg twice daily, combined with Stavudine 40 mg twice daily and Lamivudine 150 mg twice daily.
Number of subjects: 26
Study 10202820 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir-containing regimen (previous treatment).
Number of subjects: 26
Study 7717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2.5 mcg/kg intravenous bolus followed by 1 mcg/kg/h infusion
Number of subjects: 30
Study 7717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5.0 mcg/kg intravenous bolus followed by 2 mcg/kg/h infusion
Number of subjects: 30
Study 7717552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (both doses)
Number of subjects: 30
Study 7717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane administration
Number of subjects: 30
Study 7717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administration
Number of subjects: 30
Study 1479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of buprenorphine 5 micrograms.ml‐1 at 1 ml.h‐1 (group A)
Number of subjects: 150
Study 1479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of 0.25% bupivacaine at 1 ml.h‐1 (group B)
Number of subjects: 150
Study 1479654 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of buprenorphine and bupivacaine at 1 ml.h‐1 (group C)
Number of subjects: 150
Study 1479654 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 6370145 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ppm SO2 during exercise
Number of subjects: 20
Study 6370145 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ppm SO2 or less
Number of subjects: 20
Study 6370145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ppm SO2
Number of subjects: 20
Study 6370145 — intervention group
Group type: COMPARATOR
Intervention: 0.00 ppm SO2 (control)
Number of subjects: 20
Study 31518566 — intervention group
Group type: EXPERIMENTAL
Intervention: Honda's Stride Management Assist (SMA) exoskeleton
Number of subjects: 12
Study 29356610 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week group psychosocial intervention
Number of subjects: 194
Study 29356610 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus educational reading materials
Number of subjects: 194
Study 25229216 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Sb(5+)/kg/day of intramuscular meglumine antimoniate (Sb(5+)) for 30 successive days
Number of subjects: 3
Study 25229216 — intervention group
Group type: EXPERIMENTAL
Intervention: Montenegro skin test (MST)
Number of subjects: 3
Study 25229216 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment (defined as treatment applied for skin lesions less than two months old at the first appointment)
Number of subjects: 3
Study 22981148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary RBP
Number of subjects: 56
Study 22981148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary MCP‐1
Number of subjects: 56
Study 22981148 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF
Number of subjects: 56
Study 22981148 — intervention group
Group type: COMPARATOR
Intervention: TGF‐β
Number of subjects: 56
Study 22981148 — intervention group
Group type: COMPARATOR
Intervention: VEGF
Number of subjects: 56
Study 19577983 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 100
Study 19577983 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass surgery (CABG)
Number of subjects: 100
Study 19577983 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX score assessment
Number of subjects: 100
Study 19577983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer variability
Number of subjects: 100
Study 19577983 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer reproducibility
Number of subjects: 100
Study 17239677 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (36 supervised sessions, transitioning to home-based exercise)
Number of subjects: 0
Study 17239677 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 207
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 207
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 207
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving preferred treatment
Number of subjects: 207
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Not receiving preferred treatment
Number of subjects: 207
Study 14965386 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised treatment preference
Number of subjects: 207
Study 12117704 — intervention group
Group type: EXPERIMENTAL
Intervention: Average annualized weight loss of at least 1.6 kg/year
Number of subjects: 0
Study 12117704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss between 1.6 and 0.7 kg/year
Number of subjects: 0
Study 12117704 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain of more than 0.5 kg/year
Number of subjects: 0
Study 12117704 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline body mass index of less than 23.6
Number of subjects: 0
Study 12117704 — intervention group
Group type: COMPARATOR
Intervention: Referent group (weight stable and intermediate body mass index 23.6 to <28.0 kg/m2 and weight change (‐0.7 to <0.5 kg/year)
Number of subjects: 0
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025 mg/day
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.05 mg/day
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg/day
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg/day
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/day (US)
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day (Europe)
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.1 mg twice daily
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg with evening meal
Number of subjects: 704
Study 9737643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.2 mg at bedtime
Number of subjects: 704
Study 9737643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 7918266 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 39
Study 7918266 — intervention group
Group type: COMPARATOR
Intervention: 0.3% norfloxacin
Number of subjects: 39
Study 2456776 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cocaine solution (3-4 ml)
Number of subjects: 50
Study 2456776 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 50
Study 29979704 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS promoting the availability of HIV self-testing (HIVST) kits
Number of subjects: 0
Study 29979704 — intervention group
Group type: COMPARATOR
Intervention: General SMS reminding clients to test for HIV (enhanced and standard program)
Number of subjects: 0
Study 29979704 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) option within the intervention arm
Number of subjects: 0
Study 29979704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per additional client tested for FSWs
Number of subjects: 0
Study 29979704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per additional client tested for truckers
Number of subjects: 0
Study 26354534 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline total percentage body fat
Number of subjects: 294
Study 26354534 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage trunk fat
Number of subjects: 294
Study 26354534 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage abdominal fat
Number of subjects: 294
Study 26354534 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline percentage trunk and abdominal fat
Number of subjects: 294
Study 26354534 — intervention group
Group type: COMPARATOR
Intervention: Smaller percentages of fat in trunk and abdominal regions
Number of subjects: 294
Study 23833849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 micro g after spinal anesthesia)
Number of subjects: 100
Study 23833849 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin (after delivery of the baby)
Number of subjects: 100
Study 23833849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol
Number of subjects: 100
Study 23833849 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 100
Study 23833849 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 21092809 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal rotary system
Number of subjects: 50
Study 21092809 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand instrumentation technique
Number of subjects: 50
Study 21092809 — intervention group
Group type: EXPERIMENTAL
Intervention: RaCe rotary system
Number of subjects: 50
Study 21092809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo rotary system
Number of subjects: 50
Study 21092809 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 50
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: neobladder construction using the patient's intestinal tissue
Number of subjects: 0
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: sexuality-preserving surgery
Number of subjects: 0
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: robot-assisted surgery
Number of subjects: 0
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: perioperative chemotherapy
Number of subjects: 0
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: brachytherapy
Number of subjects: 0
Study 18320942 — intervention group
Group type: EXPERIMENTAL
Intervention: chemo-radiation
Number of subjects: 0
Study 16617756 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine + 3.3 microg sufentanil
Number of subjects: 91
Study 16617756 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 mg bupivacaine + 3.3 microg sufentanil
Number of subjects: 91